OncoMatch/Clinical Trials/NCT05788679
A Study Using Subject-specific MRD to Adopt Treatment After HSCT for Subjects With MDS
Is NCT05788679 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Azacitidine for myelodysplastic syndromes.
Treatment: Azacitidine — The goal of this interventional study is to evaluate if pre-emptive intervention using Azacitidine and / or donor lymphocytes or tapering of immune suppression in measurable residual disease (MRD) positive subjects can prevent clinical relapse. Participants will undergo MRD surveillance and be subjected to intervention in case of MRD positivity. Results will be compared with NMDSG14B, part one, in which MRD was analyzed in included patients without recieving intervention.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Acute Myeloid Leukemia
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify